Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)

Executive Summary

Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Advertisement

Related Content

Zelnorm's Return: US FDA Panel Hands Down Split Decision On Constipation Drug's Target Population
US FDA Seems Ready For Return Of Zelnorm, But Seeks Advice On Best Subpopulation
A Baker’s Dozen Of US FDA Efficacy Approvals Using Real World Evidence
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
Keeping Track: Shutdown Edition
Ardelyx Outlines Next Phase III Steps For Tenapanor, Ditches RDX7675
'Game-Changer' For Ardelyx As Tenapanor Phase III Is A Hit In IBS-C
Ardelyx Bets Big On Tenapanor’s Potential, Despite Side Effect Concerns
FDA's Jenkins: Patient Perspective Paramount In Assessing Risk-Benefit
Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel